Flash Finance

Aarti Pharmalabs LimitedAARTIPHARMCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹873.65
MCap ₹7,922 Cr · P/E 38.0
Aarti Pharmalabs Limited — Stock analysis & AI research Aarti Pharmalabs Limited — Multibagger AI analysis Aarti Pharmalabs Limited — Seasonality — best & worst months Aarti Pharmalabs Limited — Technical indicators & charts Aarti Pharmalabs Limited — Technical setup — score, trend, support & resistance Aarti Pharmalabs Limited — Live exchange announcements
📋 Stocks With Strong Quarterly Results 📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹535 Cr
Sales · Jun 2026
+42.4% YoY
₹136 Cr
Operating Profit · Jun 2026
+43.2% YoY
25.5%
OPM % · Jun 2026
+0.8% YoY
₹71 Cr
Net Profit · Jun 2026
+39.2% YoY
₹7.87
EPS · Jun 2026
+39.3% YoY

📝 Aarti Pharmalabs Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Aarti Pharmalabs Limited reported revenue of ₹535 crore for the quarter ended June 2026 (Q1 FY27), up 42.4% from ₹375 crore in the same quarter last year, and down 7.8% sequentially over the March 2026 quarter.

Net profit rose 39.2% year-on-year to ₹71 crore, from ₹51 crore. Earnings per share (EPS) came in at ₹7.87.

Operating profit stood at ₹136 crore — an operating margin (OPM) of 25.5%, compared with 25.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Aarti Pharmalabs Limited posted revenue of ₹1,798 crore, a growth of 1.5% over FY25, with a net profit of ₹188 crore (down 26.9% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,957 crore with a net profit of ₹208 crore.

Valuation snapshot

At the current price of ₹873.65, AARTIPHARM has a market capitalisation of ₹7,922 crore and a trailing P/E of about 38.0.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 4th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 43.08%, foreign institutional investors (FIIs) 8.39%, domestic institutional investors (DIIs) 7.40%, the government 0.01%, public shareholders 41.10% of Aarti Pharmalabs Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹7,922 Cr
Current Price ?
₹873.6
P/E ?
38.04above ind
Industry P/E ?
37.20
P/B ?
4.00
P/S ?
4.05
P/FCF ?
-41.48
Enterprise Value ?
₹8,676 Cr
EV/EBITDA ?
20.17
PEG ?
38.04
Earnings Yield ?
3.7%
Dividend Yield ?
0.56%
Profitability & Returns
Sales (TTM) ?
₹1,957 Cr
OPM ?
22.0%
Profit after tax (TTM) ?
₹208 Cr
EPS (TTM) ?
₹22.96
ROCE ?
11.0%
ROE ?
10.5%
ROA ?
6.3%
Growth
Sales — latest qtr ?
₹535 Cr
PAT — latest qtr ?
₹71 Cr
YoY qtr sales growth ?
42.4%
YoY qtr profit growth ?
39.2%
Sales growth (3y) ?
6%
Sales growth (5y) ?
N/A
Profit growth (3y) ?
1%
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹754 Cr
Debt to Equity ?
0.38
Interest Coverage ?
6.0
Current Ratio ?
N/A
Ownership
Promoter holding ?
43.08%
Change in promoter holding ?
-0.64%
Pledged percentage ?
N/A
Market
Return 3 months ?
23.4%
Return 6 months ?
25.2%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1,137374358356373415393377471530375417425580535 +42.4% -7.8%
Operating Profit 2327777748810784851151439574103117136 +43.2% +16.4%
Other Income 1050062312-323-3113 +83.7% -73.4%
Interest 156444445106711131713 +89.5% -24.3%
Depreciation 421415161717181921212325292830 +32.0% +7.2%
Profit Before Tax 17757625467916363961146742598396 +43.2% +15.9%
Net Profit 1324048424863474874895131446271 +39.2% +15.0%
EPS 14.544.415.264.615.326.955.205.288.119.805.653.414.846.847.87 +39.3% +15.1%
OPM % 20.4% 20.5% 21.4% 20.7% 23.7% 25.8% 21.3% 22.5% 24.4% 27.0% 25.3% 17.7% 24.2% 20.2% 25.5% +0.8% +26.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,772 Cr ₹1,798 Cr ₹1,957 Cr +1.5%
Operating Profit ₹426 Cr ₹389 Cr ₹430 Cr -8.7%
OPM % 24.07% 21.65% 21.98% -10.1%
NPM % 14.53% 10.47% 10.64% -27.9%
Other Income ₹14 Cr ₹13 Cr ₹14 Cr -8.9%
Depreciation ₹79 Cr ₹105 Cr ₹112 Cr +31.9%
Interest ₹25 Cr ₹47 Cr ₹54 Cr +87.3%
EBIT ₹347 Cr ₹285 Cr ₹318 Cr -18.0%
PBT ₹337 Cr ₹251 Cr ₹280 Cr -25.5%
Tax ₹54 Cr ₹27 Cr ₹36 Cr -50.8%
Net Profit ₹258 Cr ₹188 Cr ₹208 Cr -26.9%
EPS ₹28.39 ₹20.74 ₹22.96 -26.9%
Material Cost ₹655 Cr ₹438 Cr ₹504 Cr -33.2%
Employee Cost ₹112 Cr ₹84 Cr ₹93 Cr -24.5%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 45454545 +0.0%
Reserves 1,3931,5761,7991,937 +7.7%
Borrowings 208272411754 +83.5%
Other Liabilities 330404468591 +26.3%
Total Liabilities 1,9762,2972,7243,328 +22.2%
Fixed Assets 8489531,0591,525 +44.0%
CWIP 102137369305 -17.3%
Investments 55625744 -22.8%
Other Assets 9711,1451,2391,453 +17.3%
Total Assets 1,9762,2972,7243,328 +22.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 216184340257 -24.4%
Cash from Investing Activity -116-184-420-425 -1.2%
Cash from Financing Activity -157479171 +116.5%
Net Cash Flow -564-13 +400.0%
Free Cash Flow 99-5-93-191 -105.4%
CFO/OP 88%67%93%82% -11.8%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 90109114119 +4.4%
Inventory Days 240283226283 +25.2%
Days Payable 95124103144 +39.8%
Cash Conversion Cycle 235268236258 +9.3%
Working Capital Days 11813511894 -20.3%
ROCE % 16%16%17%11% -35.3%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 43.72%42.88%43.10%43.08% -0.0%
FIIs 7.34%8.02%7.69%8.39% +9.1%
DIIs 7.80%6.95%7.66%7.40% -3.4%
Government 0.01%0.01%0.01%0.01% +0.0%
Public 41.12%42.12%41.54%41.10% -1.1%
No. of Shareholders 1,87,0391,90,6551,84,4891,79,373 -2.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Aarti Pharmalabs Limited's revenue in Q1 FY27?
Aarti Pharmalabs Limited reported revenue of ₹535 crore for the quarter ended June 2026 (Q1 FY27), up 42.4% from ₹375 crore in the same quarter last year, and down 7.8% sequentially over the March 2026 quarter.
What was Aarti Pharmalabs Limited's net profit in Q1 FY27?
Net profit rose 39.2% year-on-year to ₹71 crore, from ₹51 crore. Earnings per share (EPS) came in at ₹7.87.
What is AARTIPHARM's market capitalisation and P/E ratio?
At the current price of ₹873.65, AARTIPHARM has a market capitalisation of ₹7,922 crore and a trailing P/E of about 38.0.
Who owns Aarti Pharmalabs Limited? (shareholding pattern)
As of Mar 2026, promoters held 43.08%, foreign institutional investors (FIIs) 8.39%, domestic institutional investors (DIIs) 7.40%, the government 0.01%, public shareholders 41.10% of Aarti Pharmalabs Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI